Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Apr 2;108(6):1316-23.
doi: 10.1038/bjc.2013.79. Epub 2013 Feb 28.

Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy

J M Jürgensmeier  1 , H-J Schmoll, J D Robertson, L Brooks, M Taboada, S R Morgan, D Wilson, P M Hoff
Affiliations
Clinical Trial

Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy

J M Jürgensmeier et al. Br J Cancer. .

Abstract

Background: The prognostic/predictive value of potential vascular endothelial growth factor (VEGF) signalling biomarkers was evaluated retrospectively using samples from two randomized Phase III studies (HORIZON II and III) investigating cediranib in metastatic colorectal cancer (mCRC).

Methods: Baseline levels of VEGF, soluble VEGF receptor-2 (sVEGFR-2) and carcinoembryonic antigen (CEA) were measured in plasma/serum samples collected from patients participating in HORIZON II (n=860; FOLFOX/XELOX plus cediranib 20 mg (n=502) or placebo (n=358)) and HORIZON III (n=1422; mFOLFOX6 plus cediranib 20 mg (n=709) or bevacizumab (n=713)). Median biomarker baseline levels determined cutoff values for the patient subgroups.

Results: Baseline data were available for 88-97% of patients/study (>2000 patients). In both the studies, high baseline VEGF and CEA were associated with worse outcomes for progression-free survival (PFS) and overall survival (OS) independent of treatment (HORIZON II OS: VEGF, hazard ratio (HR)=1.35 (95% confidence interval (CI): 1.12-1.63); CEA, HR=1.63 (1.36-1.96); HORIZON III OS: VEGF, HR=1.32 (1.12-1.54); CEA, HR=1.50 (1.29-1.76)). sVEGFR-2 was not prognostic for PFS/OS. Baseline VEGF and CEA were not predictive for PFS/OS outcome to cediranib treatment; low sVEGFR-2 was associated with a trend towards improved cediranib effect in HORIZON II.

Conclusion: Baseline VEGF and CEA levels were treatment-independent prognostic biomarkers for PFS and OS in both the studies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Prognostic effect of VEGF levels on PFS and OS. Effect of baseline VEGF levels on PFS outcome in (A) HORIZON II and (B) HORIZON III and on OS outcome in (C) HORIZON II and (D) HORIZON III.
Figure 2
Figure 2
Prognostic effect of CEA levels on PFS and OS. Effect of baseline CEA levels on PFS outcome in (A) HORIZON II and (B) HORIZON III and on OS outcome in (C) HORIZON II and (D) HORIZON III.
Figure 3
Figure 3
Predictive effects of baseline VEGF, sVEGFR-2 and CEA. Predictive effect of baseline VEGF, sVEGFR-2 and CEA levels on PFS and OS outcome in (A) HORIZON II and (B) HORIZON III.
See this image and copyright information in PMC

References

    1. Amaya H, Tanigawa N, Lu C, Matsumura M, Shimomatsuya T, Horiuchi T, Muraoka R. Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett. 1997;119:227–235. - PubMed
    1. Andicoechea A, Vizoso F, Alexandre E, Cuesta E, Cruz DM, Miera L, Garcia-Muniz JL, Martinez E, Ruibal A. Preoperative carbohydrate antigen 195 (CA195) and CEA serum levels as prognostic factors in patients with colorectal cancer. Int J Biol Markers. 1998;13:158–164. - PubMed
    1. de Boer RH, Arrieta Ó, Yang C-H, Gottfried M, Chan V, Raats J, De Marinis F, Abratt RP, Wolf J, Blackhall FH, Langmuir P, Milenkova T, Read J, Vansteenkiste JF. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: A randomized, double-blind Phase III trial. J Clin Oncol. 2011;29:1067–1074. - PubMed
    1. De Vita F, Orditura M, Lieto E, Infusino S, Morgillo F, Martinelli E, Castellano P, Romano C, Ciardiello F, Catalano G, Pignatelli C, Galizia G. Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer. 2004;100:270–278. - PubMed
    1. des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere J-F, Benamouzig R, Breau J-L, Perret G-Y. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer. 2006;94:1823–1832. - PMC - PubMed

Publication types

MeSH terms